Repletion of Ergothioneine in Patients With Kidney Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2027-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from our diet, is low in the blood of people receiving dialysis. For this research study, we hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

NCT01312441

Vitamin D Deficiency Renal Failure Chronic Requiring Hemodialysis

TERMINATED PHASE4

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

NCT01395823

End Stage Renal Disease

COMPLETED PHASE4

Oxidative Stress and Hemodialysis Access Failure

NCT00410449

End Stage Renal Disease Hemodialysis

COMPLETED

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

NCT03073369

CKD Chronic Kidney Diseases Hepcidin +4 more

WITHDRAWN PHASE4

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718

End-stage Renal Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esrd

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ergothioneine

Ergothioneine (range 5 mg to 25 mg) oral daily for up to 16 weeks

Group Type EXPERIMENTAL

Ergothioneine

Intervention Type DIETARY_SUPPLEMENT

This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ergothioneine

This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.

Intervention Type DIETARY_SUPPLEMENT